生物可吸收支架与依维莫司洗脱支架在心肌梗死PCI中的随机对照试验:ISAR-Absorb MI研究
ISAR-Absorb MI是一项前瞻性、随机、多中心、非劣效性临床试验,纳入262例急性心肌梗死患者,按2:1分配至依维莫司洗脱生物可吸收支架(BRS)组(n=173)或耐久聚合物依维莫司洗脱支架(EES)组(n=89)。主要终点为随访时节段内直径狭窄百分比,BRS组为24.6±12.2%,EES组为27.3±11.7%,均值差-2.7%,单侧97.5%置信上限0.7%,低于预设非劣效界值5%(P非劣效<0.001)。器械导向复合终点(心源性死亡/靶血管MI/靶病变血运重建)和明确/可能支架血栓发生率两组相当。
要点
- 在急性心肌梗死PCI患者中,BRS在随访时直径狭窄百分比上非劣效于EES。
- BRS组与EES组的器械导向复合终点事件率分别为7.0%和6.7%,无显著差异。
- 明确/可能支架血栓发生率BRS组1.7%,EES组2.3%,两组相当。
核心结论
- 在因急性心肌梗死接受PCI的患者中,BRS在血管造影随访时直径狭窄百分比方面非劣效于EES。
- 两组临床事件率相当,但研究不足以检测临床结局的差异。
研究设计与样本
- 前瞻性、随机、多中心、非劣效性临床试验,比较依维莫司洗脱BRS与耐久聚合物EES在急性MI患者中的效果。
- 纳入ST段抬高型MI或造影可见血栓的非ST段抬高型MI患者,按2:1随机分配至BRS组(n=173)或EES组(n=89),共262例。
- 血管造影随访计划在6-8个月,临床随访在12个月。
主要发现
- 主要终点随访时节段内直径狭窄百分比:BRS组24.6±12.2%,EES组27.3±11.7%,均值差-2.7%,单侧97.5%置信上限0.7%,预设非劣效界值5%,P非劣效<0.001。
- 器械导向复合终点(心源性死亡/靶血管MI/靶病变血运重建):BRS组12例(7.0%),EES组6例(6.7%),HR 1.04,95%CI 0.39-2.78。
- 明确/可能支架血栓:BRS组3例(1.7%),EES组2例(2.3%),HR 0.76,95%CI 0.13-4.56。
- 血管造影随访 available 213例(81.3%)。
关键数值与推荐
- 非劣效界值:直径狭窄百分比均值差单侧97.5%置信上限<5%。
- 主要终点:随访时节段内直径狭窄百分比。
- 器械导向复合终点包括心源性死亡、靶血管MI和靶病变血运重建。
临床怎么用
- 对于急性心肌梗死行PCI的患者,BRS可作为EES的替代选择,短期血管造影结果非劣效。
- 临床事件率两组相当,但研究未针对临床终点设计效能,选择支架时需综合考虑。
局限性
- 研究不足以检测临床结局的差异。
- 血管造影随访率81.3%,部分患者缺失随访数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Bioresorbable scaffolds (BRS) provide short-term coronary artery scaffolding and drug delivery. Although prior trials showed a higher rate of device failure compared with conventional drug-eluting stents (DES), only a single trial investigated patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction (MI). We aimed to compare outcomes with BRS vs. DES in patients undergoing PCI for MI. METHODS AND RESULTS: We did a prospective, randomized, multicentre, non-inferiority, clinical trial of everolimus-eluting BRS vs. durable polymer everolimus-eluting stents (EES) in patients with acute MI. Patients were eligible for enrolment if they presented with ST-elevation MI, or non-ST-elevation MI with thrombosis visual at angiography and were randomly allocated to treatment with BRS or EES in 2:1 proportion. Angiographic follow-up was scheduled at 6-8 months and clinical follow-up was done at 12 months. The primary endpoint was percentage diameter stenosis in-segment at follow-up. A total of 262 patients were enrolled and were allocated to BRS (n = 173) or EES (n = 89). Angiographic follow-up was available for 213 (81.3%) patients. Mean diameter stenosis was 24.6 ± 12.2% with BRS vs. 27.3 ± 11.7% with EES (mean difference -2.7%, upper limit of one-sided 97.5% confidence limit 0.7%, pre-specified margin of non-inferiority 5%, Pnon-inferiority <0.001). The rate of the device-oriented composite of cardiac death/target vessel MI/target lesion revascularization [BRS: 12 (7.0%) vs. EES: 6 (6.7%), hazard ratio (HR) 1.04, 95% confidence interval (CI) 0.39-2.78] and definite/probable stent thrombosis [3 (1.7%) vs. 2 (2.3%), HR 0.76, 95% CI 0.13-4.56] were comparable in both groups. CONCLUSION: In patients undergoing PCI for acute MI BRS were non-inferior to EES for percentage diameter stenosis at angiographic follow-up. Rates of clinical events were comparable between the treatment groups, although the study was not powered to detect differences in clinical outcomes. CLINICAL TRIAL REGISTRATION: The trial was registered at www.clinicaltrials.gov (NCT01942070).
引用
- Byrne RA, Alfonso F, Schneider S, et al. Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction: the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial. Eur Heart J. 2019. PMID: 30520980. doi:10.1093/eurheartj/ehy710
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。